Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Phase 2 Completed 75 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab

RandomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.

Timeline

Start: 1997-12
Primary completion: 2002-11
Completion: 2002-11

Publications

Results Millikan R, Thall PF, Lee SJ, Jones D, Cannon MW, Kuebler JP, Wade J 3rd, Logothetis CJ. Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer. J Clin Oncol. 2003 Mar 1;21(5):878-83. doi: 10.1200/JCO.2003.04.057.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	Oral
Subject	Ketoconazole	Small molecule	—	Oral
Subject	Paclitaxel	Small molecule	—	Intravenous
Subject	Vinblastine	Small molecule	—	Intravenous
Subject	estramustine	Other / unclassified	—	Oral

Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer

Summary

Timeline

Publications

Drugs

Indications